In an exclusive interview with Scrip, Chugai's CEO says the now 20-year-old strategic partnership with Roche has been one of the keys to Chugai’s successful growth and has allowed smooth market expansion for both firms, as well as enabling R&D investment by the Japanese firm. A flexible, platform-based approach to R&D, rather than focusing on specific target diseases or technologies, has also benefitted Chugai, Osamu Okuda noted.
CEO Osamu Okuda explains Chugai's flexible R&D strategy • Source: Lisa Takagi
For the past 20 years, major Japanese pharmaceutical firm Chugai Pharmaceutical Co., Ltd. has been a source of globally successful antibodies, including Hemlibra (emicizumab) for hemophilia and immunosuppressant Actemra (tocilizumab).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.
